Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity

por Adhikari, Hema, Kattan, Walaa E., Kumar, Shivesh, Zhou, Pei, Hancock, John F., Counter, Christopher M.
Publicado 2021

Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function

por Kattan, Walaa E, Chen, Wei, Ma, Xiaoping, Lan, Tien Hung, van der Hoeven, Dharini, van der Hoeven, Ransome, Hancock, John F
Publicado 2019

Novel CYP27B1 Gene Mutations in Patients with Vitamin D-Dependent Rickets Type 1A

por Demir, Korcan, Kattan, Walaa E., Zou, Minjing, Durmaz, Erdem, BinEssa, Huda, Nalbantoğlu, Özlem, Al-Rijjal, Roua A., Meyer, Brian, Özkan, Behzat, Shi, Yufei
Publicado 2015

Glycolysis regulates KRAS plasma membrane localization and function through defined glycosphingolipids

por Liu, Junchen, van der Hoeven, Ransome, Kattan, Walaa E., Chang, Jeffrey T., Montufar-Solis, Dina, Chen, Wei, Wong, Maurice, Zhou, Yong, Lebrilla, Carlito B., Hancock, John F.
Publicado 2023

Compressed phenotypic screens for complex multicellular models and high-content assays

por Mead, Benjamin E., Kummerlowe, Conner, Liu, Nuo, Kattan, Walaa E., Cheng, Thomas, Cheah, Jaime H., Soule, Christian K., Peters, Josh, Lowder, Kristen E., Blainey, Paul C., Hahn, William C., Cleary, Brian, Bryson, Bryan, Winter, Peter S., Raghavan, Srivatsan, Shalek, Alex K.
Publicado 2023

Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: Novel Mutations in PHEX and SLC34A3

por Acar, Sezer, BinEssa, Huda A., Demir, Korcan, Al-Rijjal, Roua A., Zou, Minjing, Çatli, Gönül, Anık, Ahmet, Al-Enezi, Anwar F., Özışık, Seçil, Al-Faham, Manar S. A., Abacı, Ayhan, Dündar, Bumin, Kattan, Walaa E., Alsagob, Maysoon, Kavukçu, Salih, Tamimi, Hamdi E., Meyer, Brian F., Böber, Ece, Shi, Yufei
Publicado 2018